{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:14:38Z","timestamp":1792109678390,"version":"4.4.0"},"reference-count":313,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K24AA025704"],"award-info":[{"award-number":["K24AA025704"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["F31AA028976"],"award-info":[{"award-number":["F31AA028976"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["F32AA029288"],"award-info":[{"award-number":["F32AA029288"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40265-021-01670-3","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T11:04:54Z","timestamp":1644318294000},"page":"251-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":168,"title":["Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-5885","authenticated-orcid":false,"given":"Elizabeth M.","family":"Burnette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica N.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R.","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Miotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artha J.","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara A.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"1670_CR1","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [Internet]. 5th ed. American Psychiatric Association; 2013 [cited 2021 Mar 15]. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"8","key":"1670_CR2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiat. 2015;72(8):757\u201366.","journal-title":"JAMA Psychiat"},{"issue":"12","key":"1670_CR3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"key":"1670_CR4","unstructured":"World Health Organization. Global status report on alcohol and health 2014. World Health Organization; 2014."},{"issue":"11","key":"1670_CR5","first-page":"E109","volume":"26","author":"M Stahre","year":"2014","unstructured":"Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;26(11):E109.","journal-title":"Prev Chronic Dis"},{"issue":"5","key":"1670_CR6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","volume":"49","author":"JJ Sacks","year":"2015","unstructured":"Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD. 2010 national and state costs of excessive alcohol consumption. Am J Prev Med. 2015;49(5):e73\u20139.","journal-title":"Am J Prev Med"},{"issue":"7","key":"1670_CR7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/archpsyc.64.7.830","volume":"64","author":"DS Hasin","year":"2007","unstructured":"Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830\u201342.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1670_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euroneuro.2012.08.001","volume":"23","author":"J Rehm","year":"2013","unstructured":"Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013;23(2):89\u201397.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 1","key":"1670_CR9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.jcp.0000248602.68607.81","volume":"26","author":"IL Petrakis","year":"2006","unstructured":"Petrakis IL. A rational approach to the pharmacotherapy of alcohol dependence. J Clin Psychopharmacol. 2006;26(Suppl 1):S3-12.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1670_CR10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11920-006-0040-0","volume":"8","author":"HM Pettinati","year":"2006","unstructured":"Pettinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep. 2006;8(5):383\u20138.","journal-title":"Curr Psychiatry Rep"},{"issue":"Suppl 17","key":"1670_CR11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15288\/jsads.2014.s17.79","volume":"75","author":"LR Zindel","year":"2014","unstructured":"Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. 2014;75(Suppl 17):79\u201388.","journal-title":"J Stud Alcohol Drugs Suppl"},{"key":"1670_CR12","doi-asserted-by":"crossref","first-page":"108964","DOI":"10.1016\/j.drugalcdep.2021.108964","volume":"227","author":"S Wallhed Finn","year":"2021","unstructured":"Wallhed Finn S, Lundin A, Sj\u00f6qvist H, Danielsson A-K. Pharmacotherapy for alcohol use disorders\u2014unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden. Drug Alcohol Depend. 2021;227:108964.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1670_CR13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","volume":"45","author":"LA Ray","year":"2019","unstructured":"Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124\u201340.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1670_CR14","unstructured":"Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 national survey on drug use and health. JAMA Psychiatry [Internet]. 2021 [cited 2021 Jun 16]. https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2781290."},{"issue":"11","key":"1670_CR15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/acer.14192","volume":"43","author":"AZ Fan","year":"2019","unstructured":"Fan AZ, Chou SP, Zhang H, Jung J, Grant BF. Prevalence and correlates of past-year recovery from DSM-5 alcohol use disorder: results from national epidemiologic survey on alcohol and related conditions-III. Alcohol Clin Exp Res. 2019;43(11):2406\u201320.","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"1670_CR16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/add.15329","volume":"116","author":"J Henssler","year":"2021","unstructured":"Henssler J, M\u00fcller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking\u2014non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression. Addiction. 2021;116(8):1973\u201387.","journal-title":"Addiction"},{"issue":"3","key":"1670_CR17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1037\/pha0000470","volume":"29","author":"TSP Fentress","year":"2021","unstructured":"Fentress TSP, Wald S, Brah A, Leemon G, Reyes R, Alkhamees F, et al. Dual study describing patient-driven harm reduction goal-setting among people experiencing homelessness and alcohol use disorder. Exp Clin Psychopharmacol. 2021;29(3):261\u201371.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"5","key":"1670_CR18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/adb.12414","volume":"22","author":"K Charlet","year":"2017","unstructured":"Charlet K, Heinz A. Harm reduction-a systematic review on effects of alcohol reduction on physical and mental symptoms. Addict Biol. 2017;22(5):1119\u201359.","journal-title":"Addict Biol"},{"issue":"11","key":"1670_CR19","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.3390\/ijerph121114828","volume":"12","author":"I Maremmani","year":"2015","unstructured":"Maremmani I, Cibin M, Pani PP, Rossi A, Turchetti G. Harm Reduction as \u201cContinuum Care\u201d in alcohol abuse disorder. Int J Environ Res Public Health. 2015;12(11):14828\u201341.","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"1670_CR20","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/add.15429","volume":"116","author":"K Witkiewitz","year":"2021","unstructured":"Witkiewitz K, Morris J, Tucker JA. Commentary on Henssler et al.: the public health case for promoting and valuing drinking reductions in the treatment of alcohol use disorder. Addiction. 2021;116(8):1988\u20139.","journal-title":"Addiction"},{"issue":"4","key":"1670_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/ADM.0000000000000760","volume":"15","author":"K Witkiewitz","year":"2021","unstructured":"Witkiewitz K, Wilson AD, Roos CR, Swan JE, Votaw VR, Stein ER, et al. Can individuals with alcohol use disorder sustain non-abstinent recovery? Non-abstinent outcomes 10 years after alcohol use disorder treatment. J Addict Med. 2021;15(4):303\u201310.","journal-title":"J Addict Med"},{"issue":"1","key":"1670_CR22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.9758\/cpn.2017.15.1.68","volume":"15","author":"S Mohapatra","year":"2017","unstructured":"Mohapatra S, Rath NR. Disulfiram induced psychosis. Clin Psychopharmacol Neurosci. 2017;15(1):68\u20139.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"4546","key":"1670_CR23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1126\/science.7071604","volume":"216","author":"RC Vallari","year":"1982","unstructured":"Vallari RC, Pietruszko R. Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram. Science. 1982;216(4546):637\u20139.","journal-title":"Science"},{"issue":"11","key":"1670_CR24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"RK Fuller","year":"1986","unstructured":"Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA. 1986;256(11):1449\u201355.","journal-title":"JAMA"},{"issue":"14","key":"1670_CR25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","volume":"281","author":"JC Garbutt","year":"1999","unstructured":"Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281(14):1318\u201325.","journal-title":"JAMA"},{"issue":"3","key":"1670_CR26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.biopsych.2012.07.011","volume":"73","author":"TR Kosten","year":"2013","unstructured":"Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine \u03b2-hydroxylase. Biol Psychiatry. 2013;73(3):219\u201324.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1670_CR27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00213-011-2447-5","volume":"219","author":"P Devoto","year":"2012","unstructured":"Devoto P, Flore G, Saba P, Cadeddu R, Gessa GL. Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex. Psychopharmacology. 2012;219(4):1153\u201364.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1670_CR28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0376-8716(87)90086-X","volume":"19","author":"G Bagdy","year":"1987","unstructured":"Bagdy G, Arat\u00f3 M. Serum dopamine-beta-hydroxylase activity and alcohol withdrawal symptoms. Drug Alcohol Depend. 1987;19(1):45\u201350.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1670_CR29","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","volume":"9","author":"MD Skinner","year":"2014","unstructured":"Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS ONE. 2014;9(2):e87366.","journal-title":"PLoS ONE"},{"issue":"3","key":"1670_CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.drugalcdep.2010.06.011","volume":"112","author":"MD Skinner","year":"2010","unstructured":"Skinner MD, Coudert M, Berlin I, Passeri E, Michel L, Aubin H-J. Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics. Drug Alcohol Depend. 2010;112(3):239\u201346.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1670_CR31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/WNF.0b013e3182216fd5","volume":"34","author":"J Mutschler","year":"2011","unstructured":"Mutschler J, Dirican G, Funke S, Obermann C, Grosshans M, Mann K, et al. Experienced acetaldehyde reaction does not improve treatment response in outpatients treated with supervised disulfiram. Clin Neuropharmacol. 2011;34(4):161\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1670_CR32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0042-103592","volume":"49","author":"J Mutschler","year":"2016","unstructured":"Mutschler J, Grosshans M, Soyka M, R\u00f6sner S. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. 2016;49(4):137\u201341.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"1670_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","volume":"99","author":"RK Fuller","year":"2004","unstructured":"Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction. 2004;99(1):21\u20134.","journal-title":"Addiction"},{"issue":"8","key":"1670_CR34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","volume":"320","author":"HR Kranzler","year":"2018","unstructured":"Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815\u201324.","journal-title":"JAMA"},{"issue":"1","key":"1670_CR35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187152710790966641","volume":"9","author":"BJ Mason","year":"2010","unstructured":"Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010;9(1):23\u201332.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"18","key":"1670_CR36","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889\u2013900.","journal-title":"JAMA"},{"issue":"2","key":"1670_CR37","first-page":"239","volume":"30","author":"FM Paille","year":"1995","unstructured":"Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239\u201347.","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"1670_CR38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","volume":"35","author":"J Chick","year":"2000","unstructured":"Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35(2):176\u201387.","journal-title":"Alcohol Alcohol"},{"issue":"6\u20137","key":"1670_CR39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.addbeh.2009.03.014","volume":"34","author":"KM Kampman","year":"2009","unstructured":"Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin DW, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav. 2009;34(6\u20137):581\u20136.","journal-title":"Addict Behav"},{"issue":"6","key":"1670_CR40","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1360-0443.2008.02215.x","volume":"103","author":"K Richardson","year":"2008","unstructured":"Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. 2008;103(6):953\u20139.","journal-title":"Addiction"},{"issue":"5","key":"1670_CR41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","volume":"40","author":"BJ Mason","year":"2006","unstructured":"Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40(5):383\u201393.","journal-title":"J Psychiatr Res"},{"issue":"17","key":"1670_CR42","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003\u201317.","journal-title":"JAMA"},{"issue":"2","key":"1670_CR43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/HRP.0000000000000079","volume":"23","author":"RM Swift","year":"2015","unstructured":"Swift RM, Aston ER. Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry. 2015;23(2):122\u201333.","journal-title":"Harv Rev Psychiatry"},{"key":"1670_CR44","doi-asserted-by":"crossref","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9):CD004332.","DOI":"10.1002\/14651858.CD004332.pub2"},{"issue":"3","key":"1670_CR45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ADM.0b013e318156c26f","volume":"1","author":"JM Littleton","year":"2007","unstructured":"Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med. 2007;1(3):115\u201325.","journal-title":"J Addict Med"},{"issue":"4","key":"1670_CR46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1530-0277.2002.tb02578.x","volume":"26","author":"GF Koob","year":"2002","unstructured":"Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res. 2002;26(4):586\u201392.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1670_CR47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0006-8993(94)01440-S","volume":"674","author":"M Davidson","year":"1995","unstructured":"Davidson M, Shanley B, Wilce P. Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study. Brain Res. 1995;674(1):91\u20136.","journal-title":"Brain Res"},{"issue":"3","key":"1670_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0014-2999(90)90022-X","volume":"176","author":"KA Grant","year":"1990","unstructured":"Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol. 1990;176(3):289\u201396.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1670_CR49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0269881107078308","volume":"22","author":"S R\u00f6sner","year":"2008","unstructured":"R\u00f6sner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11\u201323.","journal-title":"J Psychopharmacol"},{"issue":"116","key":"1670_CR50","doi-asserted-by":"crossref","first-page":"116ra6","DOI":"10.1126\/scitranslmed.3002902","volume":"4","author":"JM Mitchell","year":"2012","unstructured":"Mitchell JM, O\u2019Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med. 2012;4(116):116ra6.","journal-title":"Sci Transl Med."},{"issue":"11","key":"1670_CR51","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nn1578","volume":"8","author":"EJ Nestler","year":"2005","unstructured":"Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8(11):1445\u20139.","journal-title":"Nat Neurosci"},{"issue":"11","key":"1670_CR52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","volume":"49","author":"SS O\u2019Malley","year":"1992","unstructured":"O\u2019Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"1670_CR53","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","volume":"49","author":"JR Volpicelli","year":"1992","unstructured":"Volpicelli JR, Alterman AI, Hayashida M, O\u2019Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876\u201380.","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"1670_CR54","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","volume":"28","author":"DJ Drobes","year":"2004","unstructured":"Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004;28(9):1362\u201370.","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"1670_CR55","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.64.9.1069","volume":"64","author":"LA Ray","year":"2007","unstructured":"Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069\u201377.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1670_CR56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002130100919","volume":"160","author":"SS O\u2019Malley","year":"2002","unstructured":"O\u2019Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology. 2002;160(1):19\u201329.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1670_CR57","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.4088\/JCP.13m08934","volume":"76","author":"SS O\u2019Malley","year":"2015","unstructured":"O\u2019Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015;76(2):e207-213.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1670_CR58","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1360-0443.2001.961115654.x","volume":"96","author":"PL Morris","year":"2001","unstructured":"Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565\u201373.","journal-title":"Addiction"},{"issue":"7","key":"1670_CR59","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","volume":"99","author":"C Bouza","year":"2004","unstructured":"Bouza C, Angeles M, Magro A, Mu\u00f1oz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811\u201328.","journal-title":"Addiction"},{"issue":"5","key":"1670_CR60","first-page":"741","volume":"3","author":"BA Johnson","year":"2007","unstructured":"Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag. 2007;3(5):741\u20139.","journal-title":"Ther Clin Risk Manag"},{"issue":"13","key":"1670_CR61","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","volume":"293","author":"JC Garbutt","year":"2005","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617\u201325.","journal-title":"JAMA"},{"issue":"5","key":"1670_CR62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","volume":"22","author":"HR Kranzler","year":"2000","unstructured":"Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000;22(5):493\u2013503.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"1670_CR63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/alcalc\/36.6.544","volume":"36","author":"C Streeton","year":"2001","unstructured":"Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544\u201352.","journal-title":"Alcohol Alcohol"},{"issue":"1\u20133","key":"1670_CR64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","volume":"99","author":"TL Mark","year":"2009","unstructured":"Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1\u20133):345\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"1670_CR65","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/acer.13410","volume":"41","author":"AC Busch","year":"2017","unstructured":"Busch AC, Denduluri M, Glass J, Hetzel S, Gugnani SP, Gassman M, et al. Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study. Alcohol Clin Exp Res. 2017;41(7):1352\u201360.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR66","doi-asserted-by":"crossref","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.","DOI":"10.1002\/14651858.CD001867.pub3"},{"issue":"5","key":"1670_CR67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.18773\/austprescr.2015.063","volume":"38","author":"M McDonough","year":"2015","unstructured":"McDonough M. Naltrexone and liver disease. Aust Prescr. 2015;38(5):151.","journal-title":"Aust Prescr"},{"issue":"12","key":"1670_CR68","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","volume":"30","author":"G Bart","year":"2005","unstructured":"Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30(12):2254\u201362.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"1670_CR69","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/ijms17081216","volume":"17","author":"JH Rose","year":"2016","unstructured":"Rose JH, Karkhanis AN, Steiniger-Brach B, Jones SR. Distinct effects of nalmefene on dopamine uptake rates and kappa opioid receptor activity in the nucleus accumbens following chronic intermittent ethanol exposure. Int J Mol Sci. 2016;17(8):1216.","journal-title":"Int J Mol Sci"},{"key":"1670_CR70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.02.012","volume":"61","author":"KA Nealey","year":"2011","unstructured":"Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM. \u03ba-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology. 2011;61:35\u201342.","journal-title":"Neuropharmacology"},{"issue":"8","key":"1670_CR71","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","volume":"73","author":"K Mann","year":"2013","unstructured":"Mann K, Bladstr\u00f6m A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706\u201313.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1670_CR72","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W van den Brink","year":"2013","unstructured":"van den Brink W, Aubin H-J, Bladstr\u00f6m A, Torup L, Gual A, Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013;48(5):570\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"11","key":"1670_CR73","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","volume":"23","author":"A Gual","year":"2013","unstructured":"Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432\u201342.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"1670_CR74","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S2215-0366(16)30356-X","volume":"3","author":"F Naudet","year":"2016","unstructured":"Naudet F, Fitzgerald N, Braillon A. Nalmefene for alcohol dependence: a NICE decision? Lancet Psychiatry. 2016;3(12):1104\u20135.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"1670_CR75","doi-asserted-by":"crossref","first-page":"e1001924","DOI":"10.1371\/journal.pmed.1001924","volume":"12","author":"C Palpacuer","year":"2015","unstructured":"Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12(12):e1001924.","journal-title":"PLoS Med"},{"issue":"8","key":"1670_CR76","doi-asserted-by":"crossref","first-page":"e0183821","DOI":"10.1371\/journal.pone.0183821","volume":"12","author":"KGV Johansen","year":"2017","unstructured":"Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R. Harms associated with taking nalmefene for substance use and impulse control disorders: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE. 2017;12(8):e0183821.","journal-title":"PLoS ONE"},{"issue":"2","key":"1670_CR77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","volume":"113","author":"C Palpacuer","year":"2018","unstructured":"Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220\u201337.","journal-title":"Addiction"},{"issue":"12","key":"1670_CR78","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2215-0366(18)30419-X","volume":"5","author":"F Naudet","year":"2018","unstructured":"Naudet F, Braillon A. Baclofen and alcohol in France. Lancet Psychiatry. 2018;5(12):961\u20132.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"1670_CR79","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","volume":"5","author":"R Agabio","year":"2018","unstructured":"Agabio R, Sinclair JM, Addolorato G, Aubin H-J, Beraha EM, Caputo F, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari statement. Lancet Psychiatry. 2018;5(12):957\u201360.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1670_CR80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","volume":"9","author":"L Leggio","year":"2010","unstructured":"Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9(1):33\u201344.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"11","key":"1670_CR81","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849\u201357.","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"1670_CR82","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","volume":"37","author":"G Addolorato","year":"2002","unstructured":"Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"1670_CR83","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","volume":"49","author":"KC Morley","year":"2014","unstructured":"Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49(6):654\u201360.","journal-title":"Alcohol Alcohol"},{"issue":"8","key":"1670_CR84","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14191","volume":"113","author":"AK Rose","year":"2018","unstructured":"Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. 2018;113(8):1396\u2013406.","journal-title":"Addiction"},{"issue":"7","key":"1670_CR85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","volume":"28","author":"M Pierce","year":"2018","unstructured":"Pierce M, Sutterland A, Beraha EM, Morley K, van den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795\u2013806.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1670_CR86","doi-asserted-by":"crossref","unstructured":"Minozzi S, Saulle R, R\u00f6sner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018;11:CD012557.","DOI":"10.1002\/14651858.CD012557.pub2"},{"issue":"7","key":"1670_CR87","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","volume":"112","author":"P Hauser","year":"2017","unstructured":"Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction. 2017;112(7):1173\u201383.","journal-title":"Addiction"},{"issue":"4","key":"1670_CR88","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","volume":"52","author":"M Reynaud","year":"2017","unstructured":"Reynaud M, Aubin H-J, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients\u2014the ALPADIR study. Alcohol Alcohol. 2017;52(4):439\u201346.","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"1670_CR89","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/toxsci\/kfy073","volume":"164","author":"M Chartier","year":"2018","unstructured":"Chartier M, Tannous S, Benturquia N, Labat L, Reis R, Ris\u00e8de P, et al. Baclofen-induced neuro-respiratory toxicity in the rat: contribution of tolerance and characterization of withdrawal syndrome. Toxicol Sci. 2018;164(1):153\u201365.","journal-title":"Toxicol Sci"},{"issue":"3","key":"1670_CR90","first-page":"1","volume":"19","author":"C Santos","year":"2017","unstructured":"Santos C, Olmedo RE. Sedative-hypnotic drug withdrawal syndrome: recognition and treatment. Emerg Med Pract. 2017;19(3):1\u201320.","journal-title":"Emerg Med Pract"},{"key":"1670_CR91","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","volume":"46","author":"JC Garbutt","year":"2021","unstructured":"Garbutt JC, Kampov-Polevoy AB, Pedersen C, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacol. 2021;46:2250\u20136.","journal-title":"Neuropsychopharmacol."},{"issue":"2","key":"1670_CR92","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41380-018-0287-y","volume":"26","author":"M Farokhnia","year":"2021","unstructured":"Farokhnia M, Deschaine SL, Sadighi A, Farinelli LA, Lee MR, Akhlaghi F, et al. A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Mol Psychiatry. 2021;26(2):545\u201355.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1670_CR93","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","volume":"212","author":"KC Morley","year":"2018","unstructured":"Morley KC, Baillie A, Fraser I, Furneaux-Bate A, Dore G, Roberts M, et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018;212(6):362\u20139.","journal-title":"Br J Psychiatry"},{"issue":"9603","key":"1670_CR94","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915\u201322.","journal-title":"Lancet"},{"key":"1670_CR95","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41386-021-01142-y","volume":"46","author":"L Leggio","year":"2021","unstructured":"Leggio L, Litten RZ. The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter. Neuropsychopharmacol. 2021;46:2228\u20139.","journal-title":"Neuropsychopharmacol."},{"issue":"2","key":"1670_CR96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14740338.2020.1709821","volume":"19","author":"G Addolorato","year":"2020","unstructured":"Addolorato G, Lesch O-M, Maremmani I, Walter H, Nava F, Raffaillac Q, et al. Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. Expert Opin Drug Saf. 2020;19(2):159\u201366.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1670_CR97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","volume":"15","author":"K Skala","year":"2014","unstructured":"Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014;15(2):245\u201357.","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"1670_CR98","first-page":"4654","volume":"19","author":"FP Busard\u00f2","year":"2015","unstructured":"Busard\u00f2 FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci. 2015;19(23):4654\u201363.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1670_CR99","doi-asserted-by":"crossref","unstructured":"Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010;(2):CD006266.","DOI":"10.1002\/14651858.CD006266.pub2"},{"issue":"4","key":"1670_CR100","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","volume":"23","author":"W van den Brink","year":"2018","unstructured":"van den Brink W, Addolorato G, Aubin H-J, Benyamina A, Caputo F, Dematteis M, et al. Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol. 2018;23(4):969\u201386.","journal-title":"Addict Biol"},{"issue":"6","key":"1670_CR101","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.euroneuro.2010.12.005","volume":"21","author":"F Caputo","year":"2011","unstructured":"Caputo F, Francini S, Brambilla R, Vigna-Taglianti F, Stoppo M, Del Re A, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur Neuropsychopharmacol. 2011;21(6):450\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"13","key":"1670_CR102","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2174\/1389200219666171207122227","volume":"19","author":"C Mannucci","year":"2018","unstructured":"Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, et al. Sodium oxybate therapy for alcohol withdrawal syndrome and keeping of alcohol abstinence. Curr Drug Metab. 2018;19(13):1056\u201364.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"1670_CR103","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/ijerph8072816","volume":"8","author":"AGI Maremmani","year":"2011","unstructured":"Maremmani AGI, Pani PP, Rovai L, Pacini M, Dell\u2019Osso L, Maremmani I. Long-term \u03b3-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics. Int J Environ Res Public Health. 2011;8(7):2816\u201327.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"1670_CR104","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0269881116629126","volume":"30","author":"F Caputo","year":"2016","unstructured":"Caputo F, Maremmani AGI, Addolorato G, Domenicali M, Zoli G, D\u2019Amore A, et al. Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: a case series. J Psychopharmacol. 2016;30(4):402\u20139.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"1670_CR105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881108094620","volume":"23","author":"F Caputo","year":"2009","unstructured":"Caputo F, Francini S, Stoppo M, Lorenzini F, Vignoli T, Del Re A, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psychopharmacol. 2009;23(8):883\u201390.","journal-title":"J Psychopharmacol"},{"key":"1670_CR106","unstructured":"Department of Defense. VA\/DoD clinical practice guideline for the management of substance use disorders. 2015."},{"issue":"1","key":"1670_CR107","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","volume":"175","author":"VI Reus","year":"2018","unstructured":"Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, et al. The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86\u201390.","journal-title":"Am J Psychiatry"},{"key":"1670_CR108","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.fct.2018.05.022","volume":"118","author":"HN Shalaby","year":"2018","unstructured":"Shalaby HN, El-Tanbouly DM, Zaki HF. Topiramate mitigates 3-nitropropionic acid-induced striatal neurotoxicity via modulation of AMPA receptors. Food Chem Toxicol. 2018;118:227\u201334.","journal-title":"Food Chem Toxicol"},{"key":"1670_CR109","doi-asserted-by":"crossref","first-page":"109607","DOI":"10.1016\/j.mehy.2020.109607","volume":"138","author":"Y-L Huang","year":"2020","unstructured":"Huang Y-L, Peng M, Zhu G. Topiramate in the treatment of antipsychotic-induced hyperprolactinemia. Med Hypotheses. 2020;138:109607.","journal-title":"Med Hypotheses"},{"issue":"4","key":"1670_CR110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445\u201352.","journal-title":"Am J Psychiatry"},{"issue":"S1","key":"1670_CR111","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","volume":"41","author":"X Zhang","year":"2000","unstructured":"Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(S1):52\u201360.","journal-title":"Epilepsia"},{"issue":"9370","key":"1670_CR112","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","volume":"361","author":"BA Johnson","year":"2003","unstructured":"Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677\u201385.","journal-title":"Lancet"},{"issue":"11","key":"1670_CR113","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1530-0277.2007.00485.x","volume":"31","author":"GA Hargreaves","year":"2007","unstructured":"Hargreaves GA, McGregor IS. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res. 2007;31(11):1900\u20137.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1670_CR114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pbb.2007.04.001","volume":"87","author":"CM Knapp","year":"2007","unstructured":"Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C. Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav. 2007;87(1):65\u201372.","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"1670_CR115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00213-009-1683-4","volume":"207","author":"FJ Breslin","year":"2010","unstructured":"Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology. 2010;207(4):529\u201334.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1670_CR116","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0000000000000246","volume":"35","author":"CM Knapp","year":"2015","unstructured":"Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, et al. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34\u201342.","journal-title":"J Clin Psychopharmacol"},{"issue":"14","key":"1670_CR117","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"298","author":"BA Johnson","year":"2007","unstructured":"Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641\u201351.","journal-title":"JAMA"},{"issue":"6","key":"1670_CR118","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Re ACD, Maisel NC, Finney JW. A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481\u20138.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1670_CR119","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/ipj.ipj_57_19","volume":"28","author":"NA Jose","year":"2019","unstructured":"Jose NA, Yadav P, Kapoor A, Mahla VP. Comparison between baclofen and topiramate in alcohol dependence: a prospective study. Ind Psychiatry J. 2019;28(1):44\u201350.","journal-title":"Ind Psychiatry J"},{"issue":"2","key":"1670_CR120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1874473710902020135","volume":"2","author":"GA Kenna","year":"2009","unstructured":"Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev. 2009;2(2):135\u201342.","journal-title":"Curr Drug Abuse Rev"},{"issue":"10","key":"1670_CR121","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1345\/aph.1L157","volume":"42","author":"CL Olmsted","year":"2008","unstructured":"Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother. 2008;42(10):1475\u201380.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1670_CR122","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","volume":"6","author":"GJ Sills","year":"2006","unstructured":"Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108\u201313.","journal-title":"Curr Opin Pharmacol"},{"issue":"22","key":"1670_CR123","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1523\/JNEUROSCI.0575-08.2008","volume":"28","author":"M Roberto","year":"2008","unstructured":"Roberto M, Gilpin NW, O\u2019Dell LE, Cruz MT, Morse AC, Siggins GR, et al. Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci. 2008;28(22):5762\u201371.","journal-title":"J Neurosci"},{"key":"1670_CR124","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2015.09.027","volume":"101","author":"J Besheer","year":"2016","unstructured":"Besheer J, Frisbee S, Randall PA, Jaramillo AA, Masciello M. Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats. Neuropharmacology. 2016;101:216\u201324.","journal-title":"Neuropharmacology"},{"issue":"2","key":"1670_CR125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/acer.14269","volume":"44","author":"AR Ozburn","year":"2020","unstructured":"Ozburn AR, Metten P, Potretzke S, Townsley KG, Blednov YA, Crabbe JC. Effects of pharmacologically targeting neuroimmune pathways on alcohol drinking in mice selectively bred to drink to intoxication. Alcoho Clin Exp Res. 2020;44(2):553\u201366.","journal-title":"Alcoho Clin Exp Res."},{"issue":"11","key":"1670_CR126","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","volume":"68","author":"FA Furieri","year":"2007","unstructured":"Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691\u2013700.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"1670_CR127","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1530-0277.2008.00706.x","volume":"32","author":"KJ Brower","year":"2008","unstructured":"Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429\u201338.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1670_CR128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1369-1600.2008.00133.x","volume":"14","author":"BJ Mason","year":"2009","unstructured":"Mason BJ, Light JM, Williams LD, Drobes DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009;14(1):73\u201383.","journal-title":"Addict Biol"},{"issue":"1","key":"1670_CR129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","volume":"174","author":"BJ Mason","year":"2014","unstructured":"Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70\u20137.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1670_CR130","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e3181aba6a4","volume":"29","author":"RF Anton","year":"2009","unstructured":"Anton RF, Myrick H, Baros AM, Latham PK, Randall PK, Wright TM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009;29(4):334\u201342.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"1670_CR131","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","volume":"168","author":"RF Anton","year":"2011","unstructured":"Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709\u201317.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1670_CR132","first-page":"CD008544","volume":"13","author":"PP Pani","year":"2014","unstructured":"Pani PP, Trogu E, Pacini M, Maremmani I. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2014;13(2):CD008544.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1670_CR133","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","volume":"114","author":"HR Kranzler","year":"2019","unstructured":"Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;114(9):1547\u201355.","journal-title":"Addiction"},{"issue":"5","key":"1670_CR134","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","volume":"180","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K, Book S, Hoffman M, Prisciandaro J, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180(5):728\u201336.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1670_CR135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","volume":"43","author":"DE Falk","year":"2019","unstructured":"Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, et al. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. Alcohol Clin Exp Res. 2019;43(1):158\u201369.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR136","doi-asserted-by":"crossref","unstructured":"Wiffen PJ, Derry S, Bell RF, Rice AS, T\u00f6lle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.","DOI":"10.1002\/14651858.CD003726.pub4"},{"issue":"7","key":"1670_CR137","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160\u201374.","journal-title":"Addiction"},{"issue":"30","key":"1670_CR138","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1073\/pnas.0705368104","volume":"104","author":"P Steensland","year":"2007","unstructured":"Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA. 2007;104(30):12518\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"633","key":"1670_CR139","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neulet.2016.09.048","volume":"28","author":"OL Patkar","year":"2016","unstructured":"Patkar OL, Belmer A, Tarren JR, Holgate JY, Bartlett SE. The effect of varenicline on binge-like ethanol consumption in mice is \u03b24 nicotinic acetylcholine receptor-independent. Neurosci Lett. 2016;28(633):235\u20139.","journal-title":"Neurosci Lett"},{"key":"1670_CR140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brainresbull.2017.07.020","volume":"138","author":"HM Kamens","year":"2018","unstructured":"Kamens HM, Silva C, Peck C, Miller CN. Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL\/6J mice. Brain Res Bull. 2018;138:20\u20135.","journal-title":"Brain Res Bull"},{"issue":"9","key":"1670_CR141","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/acer.13157","volume":"40","author":"JC Froehlich","year":"2016","unstructured":"Froehlich JC, Fischer SM, Dilley JE, Nicholson ER, Smith TN, Filosa NJ, et al. Combining varenicline (Chantix) with naltrexone decreases alcohol drinking more effectively than does either drug alone in a rodent model of alcoholism. Alcohol Clin Exp Res. 2016;40(9):1961\u201370.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"1670_CR142","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","volume":"7","author":"RZ Litten","year":"2013","unstructured":"Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277\u201386.","journal-title":"J Addict Med"},{"issue":"11","key":"1670_CR143","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/acer.12854","volume":"39","author":"A de Bejczy","year":"2015","unstructured":"de Bejczy A, L\u00f6f E, Walther L, Guterstam J, Hammarberg A, Asanovska G, et al. Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2015;39(11):2189\u201399.","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"1670_CR144","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/acer.14352","volume":"44","author":"R Miranda","year":"2020","unstructured":"Miranda R, O\u2019Malley SS, Treloar Padovano H, Wu R, Falk DE, Ryan ML, et al. Effects of alcohol cue reactivity on subsequent treatment outcomes among treatment-seeking individuals with alcohol use disorder: a multisite randomized, double-blind, placebo-controlled clinical trial of varenicline. Alcohol Clin Exp Res. 2020;44(7):1431\u201343.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"1670_CR145","first-page":"201","volume":"24","author":"JC Anthony","year":"2000","unstructured":"Anthony JC, Echeagaray-Wagner F. Epidemiologic analysis of alcohol and tobacco use. Alcohol Res Health. 2000;24(4):201\u20138.","journal-title":"Alcohol Res Health"},{"issue":"2","key":"1670_CR146","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","volume":"66","author":"SA McKee","year":"2009","unstructured":"McKee SA, Harrison ELR, O\u2019Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66(2):185\u201390.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1670_CR147","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0000000000000133","volume":"9","author":"DE Falk","year":"2015","unstructured":"Falk DE, Castle I-JP, Ryan M, Fertig J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med. 2015;9(4):296\u2013303.","journal-title":"J Addict Med"},{"issue":"9","key":"1670_CR148","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/acer.14674","volume":"45","author":"S Donato","year":"2021","unstructured":"Donato S, Green R, Ray LA. Alcohol use disorder severity moderates clinical response to varenicline. Alcohol Clin Exp Res. 2021;45(9):1877\u201387.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"1670_CR149","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamapsychiatry.2017.3544","volume":"75","author":"SS O\u2019Malley","year":"2018","unstructured":"O\u2019Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking. JAMA Psychiat. 2018;75(2):129\u201338.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1670_CR150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1049909115612800","volume":"34","author":"PE Aripiprazole","year":"2017","unstructured":"Aripiprazole PE. Aripiprazole. Am J Hosp Palliat Care. 2017;34(2):180\u20135.","journal-title":"Am J Hosp Palliat Care"},{"issue":"2","key":"1670_CR151","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1254\/jphs.11201FP","volume":"118","author":"M Shibasaki","year":"2012","unstructured":"Shibasaki M, Kurokawa K, Mizuno K, Ohkuma S. Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference. J Pharmacol Sci. 2012;118(2):215\u201324.","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"1670_CR152","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/00952990.2012.730590","volume":"39","author":"R Nirogi","year":"2013","unstructured":"Nirogi R, Kandikere V, Jayarajan P, Bhyrapuneni G, Saralaya R, Muddana N, et al. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D2 receptor occupancy in rats. Am J Drug Alcohol Abuse. 2013;39(2):72\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"1670_CR153","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/alcalc\/agl037","volume":"41","author":"K Ingman","year":"2006","unstructured":"Ingman K, Kupila J, Hyyti\u00e4 P, Korpi ER. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol. 2006;41(4):391\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"4","key":"1670_CR154","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.2007.00608.x","volume":"32","author":"HR Kranzler","year":"2008","unstructured":"Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias AJ, et al. Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res. 2008;32(4):573\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"1670_CR155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0b013e3181e75cff","volume":"30","author":"H Myrick","year":"2010","unstructured":"Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol. 2010;30(4):365\u201372.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"1670_CR156","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/acer.13417","volume":"41","author":"RF Anton","year":"2017","unstructured":"Anton RF, Schacht JP, Voronin KE, Randall PK. Aripiprazole suppression of drinking in a clinical laboratory paradigm: influence of impulsivity and self-control. Alcohol Clin Exp Res. 2017;41(7):1370\u201380.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"1670_CR157","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0269881108089596","volume":"23","author":"G Martinotti","year":"2009","unstructured":"Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23(2):123\u20139.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1670_CR158","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/hup.1042","volume":"24","author":"GA Kenna","year":"2009","unstructured":"Kenna GA, Leggio L, Swift RM. A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. Hum Psychopharmacol. 2009;24(6):465\u201372.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"1670_CR159","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/alcalc\/agx108","volume":"53","author":"CL Haass-Koffler","year":"2018","unstructured":"Haass-Koffler CL, Goodyear K, Zywiak WH, Leggio L, Kenna GA, Swift RM. Comparing and combining topiramate and aripiprazole on alcohol-related outcomes in a human laboratory study. Alcohol Alcohol. 2018;53(3):268\u201376.","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"1670_CR160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","volume":"28","author":"RF Anton","year":"2008","unstructured":"Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1):5\u201312.","journal-title":"J Clin Psychopharmacol"},{"key":"1670_CR161","first-page":"7031245","volume":"2016","author":"E Heitzmann","year":"2016","unstructured":"Heitzmann E, Javelot H, Weiner L, Michel B. A case of aripiprazole-induced tardive dyskinesia with dramatic evolution. Case Rep Psychiatry. 2016;2016:7031245.","journal-title":"Case Rep Psychiatry."},{"issue":"3","key":"1670_CR162","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PRA.0000000000000157","volume":"22","author":"M Macaluso","year":"2016","unstructured":"Macaluso M, Flynn A, Preskorn S. Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and\/or dystonia in patients with major depressive disorder, part 4: case report data. J Psychiatr Pract. 2016;22(3):203\u201320.","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"1670_CR163","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002130000371","volume":"149","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 2000;149(4):327\u201344.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1670_CR164","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","volume":"75","author":"BA Johnson","year":"2008","unstructured":"Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75(1):34\u201356.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1670_CR165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.alcohol.2010.01.002","volume":"44","author":"ZA Rodd","year":"2010","unstructured":"Rodd ZA, Bell RL, Oster SM, Toalston JE, Pommer TJ, McBride WJ, et al. Serotonin-3 receptors in the posterior ventral tegmental area regulate ethanol self-administration of alcohol-preferring (P) rats. Alcohol. 2010;44(3):245\u201355.","journal-title":"Alcohol"},{"issue":"4","key":"1670_CR166","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0091-3057(95)00050-7","volume":"51","author":"AD Campbell","year":"1995","unstructured":"Campbell AD, McBride WJ. Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens. Pharmacol Biochem Behav. 1995;51(4):835\u201342.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"1670_CR167","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/FBP.0b013e3283242ff4","volume":"20","author":"SN Umathe","year":"2009","unstructured":"Umathe SN, Bhutada PS, Raut VS, Jain NS, Mundhada YR. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009;20(1):78\u201383.","journal-title":"Behav Pharmacol"},{"issue":"4","key":"1670_CR168","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF02246222","volume":"117","author":"DM Tomkins","year":"1995","unstructured":"Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology. 1995;117(4):479\u201385.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1670_CR169","first-page":"133","volume":"46","author":"W Kostowski","year":"1994","unstructured":"Kostowski W, Bisaga A, Jankowska E, Krza\u015bcik P. Studies on the effects of certain 5-HT-3 receptor antagonists on ethanol preference and withdrawal seizures in the rat. Pol J Pharmacol. 1994;46(3):133\u20137.","journal-title":"Pol J Pharmacol"},{"issue":"5","key":"1670_CR170","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","volume":"24","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24(5):737\u201342.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"1670_CR171","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","volume":"65","author":"H Myrick","year":"2008","unstructured":"Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008;65(4):466\u201375.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"1670_CR172","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","volume":"284","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284(8):963\u201371.","journal-title":"JAMA"},{"issue":"7","key":"1670_CR173","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","volume":"27","author":"HR Kranzler","year":"2003","unstructured":"Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 2003;27(7):1150\u20135.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"1670_CR174","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00213-002-1002-9","volume":"160","author":"BA Johnson","year":"2002","unstructured":"Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology. 2002;160(4):408\u201313.","journal-title":"Psychopharmacology"},{"issue":"Suppl 1","key":"1670_CR175","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(05)80255-2","volume":"29A","author":"F Roila","year":"1993","unstructured":"Roila F, Tonato M, Basurto C, Bracarda S, Sassi M, Lupattelli M, et al. Ondansetron. Eur J Cancer. 1993;29A(Suppl 1):S16-21.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1670_CR176","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/npr2.12028","volume":"38","author":"WW Shen","year":"2018","unstructured":"Shen WW. Anticraving therapy for alcohol use disorder: a clinical review. Neuropsychopharmacol Rep. 2018;38(3):105\u201316.","journal-title":"Neuropsychopharmacol Rep."},{"issue":"4","key":"1670_CR177","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/npp.2011.268","volume":"37","author":"JA Simms","year":"2012","unstructured":"Simms JA, Haass-Koffler CL, Bito-Onon J, Li R, Bartlett SE. Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking. Neuropsychopharmacology. 2012;37(4):906\u201318.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"1670_CR178","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI79828","volume":"125","author":"LF Vendruscolo","year":"2015","unstructured":"Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015;125(8):3193\u20137.","journal-title":"J Clin Invest"},{"issue":"2","key":"1670_CR179","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.120.000169","volume":"375","author":"VA Jimenez","year":"2020","unstructured":"Jimenez VA, Walter NAR, Shnitko TA, Newman N, Diem K, Vanderhooft L, et al. Mifepristone decreases chronic voluntary ethanol consumption in rhesus macaques. J Pharmacol Exp Ther. 2020;375(2):258\u201367.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1670_CR180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1037\/pha0000246","volume":"27","author":"AF Holtyn","year":"2019","unstructured":"Holtyn AF, Weerts EM. Evaluation of mifepristone effects on alcohol-seeking and self-administration in baboons. Exp Clin Psychopharmacol. 2019;27(3):227\u201335.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"16","key":"1670_CR181","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12888-016-0757-1","volume":"24","author":"K Donoghue","year":"2016","unstructured":"Donoghue K, Rose A, Coulton S, Milward J, Reed K, Drummond C, et al. Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry. 2016;24(16):40.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1670_CR182","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1186\/s13063-020-04726-z","volume":"21","author":"K Donoghue","year":"2020","unstructured":"Donoghue K, Rose A, Coulton S, Coleman R, Milward J, Philips T, et al. Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence. Trials. 2020;21(1):796.","journal-title":"Trials"},{"issue":"1\u20133","key":"1670_CR183","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2006.02.053","volume":"538","author":"LCD Gibson","year":"2006","unstructured":"Gibson LCD, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006;538(1\u20133):39\u201342.","journal-title":"Eur J Pharmacol"},{"issue":"25","key":"1670_CR184","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1073\/pnas.1002716107","volume":"107","author":"Y Cho","year":"2010","unstructured":"Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA. 2010;107(25):11313\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1670_CR185","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2003.09.009","volume":"46","author":"T Mizuno","year":"2004","unstructured":"Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46(3):404\u201311.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1670_CR186","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/npp.2016.177","volume":"42","author":"J Mayfield","year":"2017","unstructured":"Mayfield J, Harris RA. The neuroimmune basis of excessive alcohol consumption. Neuropsychopharmacology. 2017;42(1):376.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1670_CR187","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4155\/cli.14.8","volume":"4","author":"K Johnson","year":"2014","unstructured":"Johnson K, Matsuda K, Iwaki Y. Ibudilast for the treatment of drug addiction and other neurological conditions. Clin Investig. 2014;4(3):269\u201379.","journal-title":"Clin Investig"},{"issue":"1","key":"1670_CR188","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/adb.12106","volume":"20","author":"RL Bell","year":"2015","unstructured":"Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Franklin KM, et al. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol. 2015;20(1):38\u201342.","journal-title":"Addict Biol"},{"key":"1670_CR189","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnins.2014.00129","volume":"8","author":"YA Blednov","year":"2014","unstructured":"Blednov YA, Benavidez JM, Black M, Harris RA. Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL\/6J mice. Front Neurosci. 2014;8:129.","journal-title":"Front Neurosci"},{"issue":"7","key":"1670_CR190","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/npp.2014.20","volume":"39","author":"ML Logrip","year":"2014","unstructured":"Logrip ML, Vendruscolo LF, Schlosburg JE, Koob GF, Zorrilla EP. Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacology. 2014;39(7):1722\u201331.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"1670_CR191","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/j.1530-0277.2012.01845.x","volume":"36","author":"R-T Wen","year":"2012","unstructured":"Wen R-T, Zhang M, Qin W-J, Liu Q, Wang W-P, Lawrence AJ, et al. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. Alcohol Clin Exp Res. 2012;36(12):2157\u201367.","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"1670_CR192","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/npp.2017.10","volume":"42","author":"LA Ray","year":"2017","unstructured":"Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K, Miotto K. Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology. 2017;42(9):1776\u201388.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1670_CR193","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41398-021-01478-5","volume":"11","author":"EN Grodin","year":"2021","unstructured":"Grodin EN, Bujarski S, Towns B, Burnette E, Nieto S, Lim A, et al. Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. Transl Psychiatry. 2021;11(1):355.","journal-title":"Transl Psychiatry"},{"issue":"10","key":"1670_CR194","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/acer.14696","volume":"45","author":"EM Burnette","year":"2021","unstructured":"Burnette EM, Ray LA, Irwin MR, Grodin EN. Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder. Alcohol Clin Exp Res. 2021;45(10):2017\u201328.","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"1670_CR195","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2125.2008.03270.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan P, Gibbons JA, He L, Chang E, Jones D, Gross MI, et al. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol. 2008;66(6):792\u2013801.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1670_CR196","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","volume":"379","author":"RJ Fox","year":"2018","unstructured":"Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"1670_CR197","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0014-2999(95)00062-P","volume":"276","author":"H Sommermeyer","year":"1995","unstructured":"Sommermeyer H, Frielingsdorf J, Knorr A. Effects of prazosin on the dopaminergic neurotransmission in rat brain. Eur J Pharmacol. 1995;276(3):267\u201370.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1670_CR198","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/acer.12064","volume":"37","author":"L Leggio","year":"2013","unstructured":"Leggio L, Kenna GA. Doxasozin for alcoholism. Alcohol Clin Exp Res. 2013;37(2):191\u20133.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR199","doi-asserted-by":"crossref","first-page":"581098","DOI":"10.3389\/fphar.2020.581098","volume":"11","author":"DM Perez","year":"2020","unstructured":"Perez DM. \u03b11-Adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front Pharmacol. 2020;11:581098.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1670_CR200","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00213-018-4843-6","volume":"235","author":"CL Haass-Koffler","year":"2018","unstructured":"Haass-Koffler CL, Swift RM, Leggio L. Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology. 2018;235(6):1625\u201334.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1670_CR201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.alcohol.2007.12.002","volume":"42","author":"BM Walker","year":"2008","unstructured":"Walker BM, Rasmussen DD, Raskind MA, Koob GF. alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol. 2008;42(2):91\u20137.","journal-title":"Alcohol"},{"issue":"11","key":"1670_CR202","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00213-016-4273-2","volume":"233","author":"D Funk","year":"2016","unstructured":"Funk D, Coen K, Tamadon S, Li Z, Loughlin A, L\u00ea AD. Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats. Psychopharmacology. 2016;233(11):2197\u2013207.","journal-title":"Psychopharmacology"},{"issue":"8","key":"1670_CR203","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/acer.12789","volume":"39","author":"JC Froehlich","year":"2015","unstructured":"Froehlich JC, Hausauer B, Fischer S, Wise B, Rasmussen DD. Prazosin reduces alcohol intake in an animal model of alcohol relapse. Alcohol Clin Exp Res. 2015;39(8):1538\u201346.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"1670_CR204","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1530-0277.2012.01884.x","volume":"37","author":"ML O\u2019Neil","year":"2013","unstructured":"O\u2019Neil ML, Beckwith LE, Kincaid CL, Rasmussen DD. The \u03b11-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res. 2013;37(2):202\u201312.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.alcohol.2020.07.005","volume":"89","author":"MF Lopez","year":"2020","unstructured":"Lopez MF, Reasons SE, Carper BA, Nolen TL, Williams RL, Becker HC. Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress. Alcohol. 2020;89:37\u201342.","journal-title":"Alcohol"},{"issue":"2","key":"1670_CR206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","volume":"33","author":"TL Simpson","year":"2009","unstructured":"Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009;33(2):255\u201363.","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"1670_CR207","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1176\/appi.ajp.2018.17080913","volume":"175","author":"TL Simpson","year":"2018","unstructured":"Simpson TL, Saxon AJ, Stappenbeck C, Malte CA, Lyons R, Tell D, et al. Double-blind randomized clinical trial of the \u03b1\u22121 noradrenergic antagonist prazosin for alcohol use disorder. Am J Psychiatry. 2018;175(12):1216\u201324.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1670_CR208","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/adb.12275","volume":"21","author":"GA Kenna","year":"2016","unstructured":"Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, et al. Role of the \u03b11 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol. 2016;21(4):904\u201314.","journal-title":"Addict Biol"},{"issue":"177","key":"1670_CR209","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.03.016","volume":"1","author":"CL Haass-Koffler","year":"2017","unstructured":"Haass-Koffler CL, Goodyear K, Zywiak WH, Magill M, Eltinge SE, Wallace PM, et al. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend. 2017;1(177):23\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"1670_CR210","doi-asserted-by":"publisher","unstructured":"Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, et al. Moderation of Prazosin\u2019s efficacy by alcohol withdrawal symptoms. American Journal of Psychiatry [Internet]. 2020 [cited 2021 Sep 16]. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20050609.","DOI":"10.1176\/appi.ajp.2020.20050609"},{"issue":"5","key":"1670_CR211","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/add.15265","volume":"116","author":"P Vanderkam","year":"2021","unstructured":"Vanderkam P, Solinas M, Ingrand I, Doux N, Ebrahimighavam S, Jaafari N, et al. Effectiveness of drugs acting on adrenergic receptors in the treatment for tobacco or alcohol use disorders: systematic review and meta-analysis. Addiction. 2021;116(5):1011\u201320.","journal-title":"Addiction"},{"key":"1670_CR212","doi-asserted-by":"crossref","first-page":"173037","DOI":"10.1016\/j.pbb.2020.173037","volume":"198","author":"WW Stoops","year":"2020","unstructured":"Stoops WW, Strickland JC, Hays LR, Rayapati AO, Lile JA, Rush CR. Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol. Pharmacol Biochem Behav. 2020;198:173037.","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"1670_CR213","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1046\/j.1471-4159.1997.69041559.x","volume":"69","author":"X Chen","year":"1997","unstructured":"Chen X, Michaelis ML, Michaelis EK. Effects of chronic ethanol treatment on the expression of calcium transport carriers and NMDA\/glutamate receptor proteins in brain synaptic membranes. J Neurochem. 1997;69(4):1559\u201369.","journal-title":"J Neurochem"},{"issue":"2\u20133","key":"1670_CR214","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-2999(02)02851-0","volume":"459","author":"A Dahchour","year":"2003","unstructured":"Dahchour A, De Witte P. Excitatory and inhibitory amino acid changes during repeated episodes of ethanol withdrawal: an in vivo microdialysis study. Eur J Pharmacol. 2003;459(2\u20133):171\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1670_CR215","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/adb.12521","volume":"23","author":"S Lebourgeois","year":"2018","unstructured":"Lebourgeois S, Gonz\u00e1lez-Mar\u00edn MC, Jeanblanc J, Naassila M, Vilpoux C. Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration. Addict Biol. 2018;23(2):643\u201352.","journal-title":"Addict Biol"},{"issue":"150","key":"1670_CR216","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2019.03.010","volume":"15","author":"S Lebourgeois","year":"2019","unstructured":"Lebourgeois S, Gonz\u00e1lez-Mar\u00edn MC, Antol J, Naassila M, Vilpoux C. Evaluation of N-acetylcysteine on ethanol self-administration in ethanol-dependent rats. Neuropharmacology. 2019;15(150):112\u201320.","journal-title":"Neuropharmacology"},{"issue":"93","key":"1670_CR217","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pnpbp.2019.03.014","volume":"13","author":"R Mocelin","year":"2019","unstructured":"Mocelin R, Marcon M, da Rosa Araujo AS, Herrmann AP, Piato A. Withdrawal effects following repeated ethanol exposure are prevented by N-acetylcysteine in zebrafish. Prog Neuropsychopharmacol Biol Psychiatry. 2019;13(93):161\u201370.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Pt A","key":"1670_CR218","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2016.07.009","volume":"110","author":"G Morais-Silva","year":"2016","unstructured":"Morais-Silva G, Alves GC, Marin MT. N-Acetylcysteine treatment blocks the development of ethanol-induced behavioural sensitization and related \u0394FosB alterations. Neuropharmacology. 2016;110(Pt A):135\u201342.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1670_CR219","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.alcohol.2015.01.009","volume":"49","author":"R Schneider","year":"2015","unstructured":"Schneider R, Santos CF, Clarimundo V, Dalmaz C, Elisabetsky E, Gomez R. N-Acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats. Alcohol. 2015;49(3):259\u201363.","journal-title":"Alcohol"},{"issue":"8","key":"1670_CR220","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s11064-017-2218-8","volume":"42","author":"R Schneider","year":"2017","unstructured":"Schneider R, Bandiera S, Souza DG, Bellaver B, Caletti G, Quincozes-Santos A, et al. N-Acetylcysteine prevents alcohol related neuroinflammation in rats. Neurochem Res. 2017;42(8):2135\u201341.","journal-title":"Neurochem Res"},{"issue":"1","key":"1670_CR221","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12853","volume":"26","author":"Y Israel","year":"2021","unstructured":"Israel Y, Quintanilla ME, Ezquer F, Morales P, Santapau D, Berr\u00edos-C\u00e1rcamo P, Ezquer M, Olivares B, Herrera-Marschitz M. Aspirin and N-acetylcysteine co-administration markedly inhibit chronic ethanol intake and block relapse binge drinking: Role of neuroinflammation-oxidative stress self-perpetuation. Addict Biol. 2021;26(1):e12853.","journal-title":"Addict Biol."},{"issue":"7","key":"1670_CR222","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ajad.12620","volume":"26","author":"MS Duailibi","year":"2017","unstructured":"Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, LaRowe S, Berk M, et al. N-Acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis. Am J Addict. 2017;26(7):660\u20136.","journal-title":"Am J Addict"},{"issue":"185","key":"1670_CR223","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","volume":"01","author":"LM Squeglia","year":"2018","unstructured":"Squeglia LM, Tomko RL, Baker NL, McClure EA, Book GA, Gray KM. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018;01(185):17\u201322.","journal-title":"Drug Alcohol Depend"},{"key":"1670_CR224","doi-asserted-by":"crossref","first-page":"105961","DOI":"10.1016\/j.cct.2020.105961","volume":"91","author":"SE Back","year":"2020","unstructured":"Back SE, Gray K, Ana ES, Jones JL, Jarnecke AM, Joseph JE, et al. N-Acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: design and methodology of a randomized clinical trial. Contemp Clin Trials. 2020;91:105961.","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"1670_CR225","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.chc.2016.05.004","volume":"25","author":"CJ Hammond","year":"2016","unstructured":"Hammond CJ. The role of pharmacotherapy in the treatment of adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(4):685\u2013711.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"6","key":"1670_CR226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40495-016-0069-7","volume":"2","author":"LC Walker","year":"2016","unstructured":"Walker LC, Ch\u2019ng SS, Lawrence AJ. Role of lateral hypothalamic orexin (hypocretin) neurons in alcohol use and abuse: recent advances. Curr Pharmacol Rep. 2016;2(6):241\u201352.","journal-title":"Curr Pharmacol Rep."},{"issue":"1","key":"1670_CR227","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1523\/JNEUROSCI.23-01-00007.2003","volume":"23","author":"TM Korotkova","year":"2003","unstructured":"Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins\/hypocretins. J Neurosci. 2003;23(1):7\u201311.","journal-title":"J Neurosci"},{"issue":"1","key":"1670_CR228","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(00)02555-5","volume":"873","author":"T Nakamura","year":"2000","unstructured":"Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000;873(1):181\u20137.","journal-title":"Brain Res"},{"key":"1670_CR229","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fnins.2019.00088","volume":"13","author":"K Lei","year":"2019","unstructured":"Lei K, Kwok C, Darevsky D, Wegner SA, Yu J, Nakayama L, et al. Nucleus accumbens shell orexin-1 receptors are critical mediators of binge intake in excessive-drinking individuals. Front Neurosci. 2019;13:88.","journal-title":"Front Neurosci"},{"issue":"Pt A","key":"1670_CR230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2016.10.018","volume":"1654","author":"DE Moorman","year":"2017","unstructured":"Moorman DE, James MH, Kilroy EA, Aston-Jones G. Orexin\/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats. Brain Res. 2017;1654(Pt A):34\u201342.","journal-title":"Brain Res"},{"key":"1670_CR231","doi-asserted-by":"crossref","unstructured":"Brown RM, Kim AK, Khoo SY-S, Kim JH, Jupp B, Lawrence AJ. Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats. Addict Biol. 2016;21(3):603\u201312.","DOI":"10.1111\/adb.12251"},{"issue":"6","key":"1670_CR232","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.04.021","volume":"79","author":"M Ubaldi","year":"2016","unstructured":"Ubaldi M, Giordano A, Severi I, Li H, Kallupi M, de Guglielmo G, et al. Activation of hypocretin-1\/orexin-a neurons projecting to the bed nucleus of the stria terminalis and paraventricular nucleus is critical for reinstatement of alcohol seeking by neuropeptide S. Biol Psychiatry. 2016;79(6):452\u201362.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"1670_CR233","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.bjp.0706789","volume":"148","author":"AJ Lawrence","year":"2006","unstructured":"Lawrence AJ, Cowen MS, Yang H-J, Chen F, Oldfield B. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol. 2006;148(6):752\u20139.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1670_CR234","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-010-2127-x","volume":"215","author":"JR Shoblock","year":"2011","unstructured":"Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K, et al. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology. 2011;215(1):191\u2013203.","journal-title":"Psychopharmacology"},{"issue":"9","key":"1670_CR235","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1017\/S1461145713000333","volume":"16","author":"RM Brown","year":"2013","unstructured":"Brown RM, Khoo SY-S, Lawrence AJ. Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. Int J Neuropsychopharmacol. 2013;16(9):2067\u201379.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"1670_CR236","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/adb.12139","volume":"20","author":"JR Barson","year":"2015","unstructured":"Barson JR, Ho HT, Leibowitz SF. Anterior thalamic paraventricular nucleus is involved in intermittent access ethanol drinking: role of orexin receptor 2. Addict Biol. 2015;20(3):469\u201381.","journal-title":"Addict Biol"},{"key":"1670_CR237","first-page":"33","volume":"8","author":"RI Anderson","year":"2014","unstructured":"Anderson RI, Becker HC, Adams BL, Jesudason CD, Rorick-Kehn LM. Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. Front Neurosci. 2014;8:33.","journal-title":"Front Neurosci"},{"issue":"9","key":"1670_CR238","doi-asserted-by":"crossref","first-page":"e44726","DOI":"10.1371\/journal.pone.0044726","volume":"7","author":"S Srinivasan","year":"2012","unstructured":"Srinivasan S, Simms JA, Nielsen CK, Lieske SP, Bito-Onon JJ, Yi H, et al. The dual orexin\/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. PLoS ONE. 2012;7(9):e44726.","journal-title":"PLoS ONE"},{"issue":"1728","key":"1670_CR239","doi-asserted-by":"crossref","first-page":"146597","DOI":"10.1016\/j.brainres.2019.146597","volume":"1","author":"EJ Campbell","year":"2020","unstructured":"Campbell EJ, Norman A, Bonomo Y, Lawrence AJ. Suvorexant to treat alcohol use disorder and comorbid insomnia: plan for a phase II trial. Brain Res. 2020;1(1728):146597.","journal-title":"Brain Res"},{"issue":"11","key":"1670_CR240","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0269881115609015","volume":"29","author":"H Sun","year":"2015","unstructured":"Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, et al. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. J Psychopharmacol. 2015;29(11):1159\u201369.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"1670_CR241","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1530-0277.2011.01532.x","volume":"35","author":"Y Zhou","year":"2011","unstructured":"Zhou Y, Colombo G, Carai MAM, Ho A, Gessa GL, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res. 2011;35(10):1876\u201383.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1670_CR242","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1369-1600.2010.00291.x","volume":"17","author":"S Edwards","year":"2012","unstructured":"Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF. Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol. 2012;17(1):76\u201385.","journal-title":"Addict Biol"},{"issue":"4","key":"1670_CR243","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/acer.12996","volume":"40","author":"DA Katz","year":"2016","unstructured":"Katz DA, Locke C, Liu W, Zhang J, Achari R, Wesnes KA, et al. Single-dose interaction study of the arginine vasopressin type 1B receptor antagonist ABT-436 and alcohol in moderate alcohol drinkers. Alcohol Clin Exp Res. 2016;40(4):838\u201345.","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"1670_CR244","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/npp.2016.214","volume":"42","author":"ML Ryan","year":"2017","unstructured":"Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, et al. A phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology. 2017;42(5):1012\u201323.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1670_CR245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/alcalc\/agv094","volume":"51","author":"MC Tomasini","year":"2016","unstructured":"Tomasini MC, Borelli AC, Beggiato S, Tanganelli S, Loche A, Cacciaglia R, et al. GET73 prevents ethanol-induced neurotoxicity in primary cultures of rat hippocampal neurons. Alcohol Alcohol. 2016;51(2):128\u201335.","journal-title":"Alcohol Alcohol"},{"key":"1670_CR246","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fpsyt.2012.00008","volume":"3","author":"A Loche","year":"2012","unstructured":"Loche A, Simonetti F, Lobina C, Carai MAM, Colombo G, Castelli MP, et al. Anti-alcohol and anxiolytic properties of a new chemical entity, GET73. Front Psychiatry. 2012;3:8.","journal-title":"Front Psychiatry."},{"key":"1670_CR247","first-page":"95","volume":"3","author":"G Colombo","year":"2012","unstructured":"Colombo G, Carai MAM, Gessa GL. Suppression by \u03b3-hydroxybutyric acid of \u201calcohol deprivation effect\u201d in rats: preclinical evidence of its anti-relapse properties. Front Psychiatry. 2012;3:95.","journal-title":"Front Psychiatry."},{"key":"1670_CR248","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fphar.2018.00327","volume":"9","author":"S Beggiato","year":"2018","unstructured":"Beggiato S, Borelli AC, Tomasini MC, Castelli MP, Pintori N, Cacciaglia R, et al. In vitro functional characterization of GET73 as possible negative allosteric modulator of metabotropic glutamate receptor 5. Front Pharmacol. 2018;9:327.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1670_CR249","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0269881117746904","volume":"32","author":"CL Haass-Koffler","year":"2018","unstructured":"Haass-Koffler CL, Goodyear K, Loche A, Long VM, Lobina C, Tran HH, et al. Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: a translational study in rats and humans. J Psychopharmacol. 2018;32(2):163\u201373.","journal-title":"J Psychopharmacol"},{"issue":"109","key":"1670_CR250","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejps.2017.07.031","volume":"15","author":"CL Haass-Koffler","year":"2017","unstructured":"Haass-Koffler CL, Goodyear K, Long VM, Tran HH, Loche A, Cacciaglia R, et al. A phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers. Eur J Pharm Sci. 2017;15(109):78\u201385.","journal-title":"Eur J Pharm Sci"},{"key":"1670_CR251","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00213-021-06008-1","volume":"239","author":"CL Haass-Koffler","year":"2022","unstructured":"Haass-Koffler CL, Perciballi R, Magill M, et al. An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. Psychopharmacology (Berl). 2022;239:35\u201346.","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"1670_CR252","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40263-018-0596-3","volume":"33","author":"P Maccioni","year":"2019","unstructured":"Maccioni P, Colombo G. Potential of gabab receptor positive allosteric modulators in the treatment of alcohol use disorder. CNS Drugs. 2019;33(2):107\u201323.","journal-title":"CNS Drugs"},{"issue":"1","key":"1670_CR253","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/pr.109.002501","volume":"63","author":"S Urwyler","year":"2011","unstructured":"Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev. 2011;63(1):59\u2013126.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"1670_CR254","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2006.03660.x","volume":"96","author":"T Gjoni","year":"2006","unstructured":"Gjoni T, Desrayaud S, Imobersteg S, Urwyler S. The positive allosteric modulator GS39783 enhances GABA(B) receptor-mediated inhibition of cyclic AMP formation in rat striatum in vivo. J Neurochem. 2006;96(5):1416\u201322.","journal-title":"J Neurochem"},{"key":"1670_CR255","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnins.2014.00140","volume":"8","author":"R Agabio","year":"2014","unstructured":"Agabio R, Colombo G. GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci. 2014;8:140.","journal-title":"Front Neurosci"},{"issue":"9","key":"1670_CR256","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/npp.2017.53","volume":"42","author":"E Augier","year":"2017","unstructured":"Augier E, Dulman RS, Damadzic R, Pilling A, Hamilton JP, Heilig M. The GABAB positive allosteric modulator ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats. Neuropsychopharmacology. 2017;42(9):1789\u201399.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"1670_CR257","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00213-018-4893-9","volume":"235","author":"V Vengeliene","year":"2018","unstructured":"Vengeliene V, Takahashi TT, Dravolina OA, Belozertseva I, Zvartau E, Bespalov AY, et al. Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. Psychopharmacology. 2018;235(7):1955\u201365.","journal-title":"Psychopharmacology"},{"issue":"17","key":"1670_CR258","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00213-017-4644-3","volume":"234","author":"P Maccioni","year":"2017","unstructured":"Maccioni P, Colombo G, Lorrai I, Zaru A, Carai MAM, Gessa GL, et al. Suppressing effect of COR659 on alcohol, sucrose, and chocolate self-administration in rats: involvement of the GABAB and cannabinoid CB1 receptors. Psychopharmacology. 2017;234(17):2525\u201343.","journal-title":"Psychopharmacology"},{"key":"1670_CR259","doi-asserted-by":"crossref","first-page":"172750","DOI":"10.1016\/j.ejphar.2019.172750","volume":"865","author":"N Murai","year":"2019","unstructured":"Murai N, Kondo Y, Akuzawa S, Mihara T, Shiraishi N, Kakimoto S, et al. A novel GABAB receptor positive allosteric modulator, ASP8062, exerts analgesic effects in a rat model of fibromyalgia. Eur J Pharmacol. 2019;865:172750.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1670_CR260","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpdd.766","volume":"9","author":"M Walzer","year":"2020","unstructured":"Walzer M, Marek GJ, Wu R, Nagata M, Han D. Single- and multiple-dose safety, tolerability, and pharmacokinetic profiles of ASP8062: results from 2 phase 1 studies. Clin Pharmacol Drug Dev. 2020;9(3):297\u2013306.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"6762","key":"1670_CR261","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656\u201360.","journal-title":"Nature"},{"issue":"6","key":"1670_CR262","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","volume":"4","author":"TD M\u00fcller","year":"2015","unstructured":"M\u00fcller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. 2015;4(6):437\u201360.","journal-title":"Mol Metab."},{"issue":"3","key":"1670_CR263","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1358\/dnp.2010.23.3.1429490","volume":"23","author":"L Leggio","year":"2010","unstructured":"Leggio L. Role of the ghrelin system in alcoholism: acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. Drug News Perspect. 2010;23(3):157\u201366.","journal-title":"Drug News Perspect"},{"issue":"9","key":"1670_CR264","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2014.03.019","volume":"76","author":"L Leggio","year":"2014","unstructured":"Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, et al. Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry. 2014;76(9):734\u201341.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"1670_CR265","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/mp.2017.226","volume":"23","author":"M Farokhnia","year":"2018","unstructured":"Farokhnia M, Grodin EN, Lee MR, Oot EN, Blackburn AN, Stangl BL, et al. Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals. Mol Psychiatry. 2018;23(10):2029\u201338.","journal-title":"Mol Psychiatry"},{"issue":"27","key":"1670_CR266","doi-asserted-by":"crossref","first-page":"11318","DOI":"10.1073\/pnas.0812809106","volume":"106","author":"E Jerlhag","year":"2009","unstructured":"Jerlhag E, Egecioglu E, Landgren S, Salom\u00e9 N, Heilig M, Moechars D, et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci USA. 2009;106(27):11318\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1670_CR267","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1530-0277.2010.01237.x","volume":"34","author":"S Kaur","year":"2010","unstructured":"Kaur S, Ryabinin AE. Ghrelin receptor antagonism decreases alcohol consumption and activation of perioculomotor urocortin-containing neurons. Alcohol Clin Exp Res. 2010;34(9):1525\u201334.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR268","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuropharm.2015.05.026","volume":"97","author":"JL Gomez","year":"2015","unstructured":"Gomez JL, Cunningham CL, Finn DA, Young EA, Helpenstell LK, Schuette LM, et al. Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence. Neuropharmacology. 2015;97:182\u201393.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1670_CR269","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1369-1600.2010.00280.x","volume":"17","author":"S Landgren","year":"2012","unstructured":"Landgren S, Simms JA, Hyyti\u00e4 P, Engel JA, Bartlett SE, Jerlhag E. Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats. Addict Biol. 2012;17(1):86\u201394.","journal-title":"Addict Biol"},{"issue":"155","key":"1670_CR270","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.physbeh.2015.12.017","volume":"1","author":"JR Stevenson","year":"2016","unstructured":"Stevenson JR, Francomacaro LM, Bohidar AE, Young KA, Pesarchick BF, Buirkle JM, et al. Ghrelin receptor (GHS-R1A) antagonism alters preference for ethanol and sucrose in a concentration-dependent manner in prairie voles. Physiol Behav. 2016;1(155):231\u20136.","journal-title":"Physiol Behav"},{"issue":"9","key":"1670_CR271","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/bph.13439","volume":"173","author":"J Kong","year":"2016","unstructured":"Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, et al. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. Br J Pharmacol. 2016;173(9):1452\u201364.","journal-title":"Br J Pharmacol"},{"key":"1670_CR272","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0064-y","author":"MR Lee","year":"2018","unstructured":"Lee MR, Tapocik JD, Ghareeb M, Schwandt ML, Dias AA, Le AN, et al. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Mol Psychiatry. 2018. https:\/\/doi.org\/10.1038\/s41380-018-0064-y.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1670_CR273","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bcp.13127","volume":"83","author":"WS Denney","year":"2017","unstructured":"Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. Pharmacokinetics and pharmacodynamics of PF-05190457: the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin Pharmacol. 2017;83(2):326\u201338.","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"1670_CR274","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805.","journal-title":"Br J Pharmacol"},{"key":"1670_CR275","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, F F, Ferreiro-Vera C, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB 2 receptors. Frontiers in pharmacology [Internet]. 2017 [cited 2021 Aug 30];8. https:\/\/pubmed.ncbi.nlm.nih.gov\/29109685\/.","DOI":"10.3389\/fphar.2017.00744"},{"issue":"2","key":"1670_CR276","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199\u2013215.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1670_CR277","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037\u201343.","journal-title":"Neurochem Res"},{"issue":"5","key":"1670_CR278","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","volume":"372","author":"M Kathmann","year":"2006","unstructured":"Kathmann M, Flau K, Redmer A, Tr\u00e4nkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372(5):354\u201361.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1670_CR279","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fphar.2019.00627","volume":"10","author":"J De Ternay","year":"2019","unstructured":"De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, et al. Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain. Front Pharmacol. 2019;10:627.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1670_CR280","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","volume":"43","author":"J Turna","year":"2019","unstructured":"Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, et al. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res. 2019;43(4):550\u201363.","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"1670_CR281","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911\u201322.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1670_CR282","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7(10):865\u201374.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"1670_CR283","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/acer.13093","volume":"40","author":"RZ Litten","year":"2016","unstructured":"Litten RZ, Falk DE, Ryan ML, Fertig JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res. 2016;40(7):1368\u201379.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR284","first-page":"1","volume":"31","author":"A Venegas","year":"2021","unstructured":"Venegas A, Donato S, Meredith LR, Ray LA. Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement. Am J Drug Alcohol Abuse. 2021;31:1\u201316.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"13","key":"1670_CR285","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-021-01069-4","volume":"46","author":"ND Volkow","year":"2021","unstructured":"Volkow ND, Gordon JA, Koob GF. Choosing appropriate language to reduce the stigma around mental illness and substance use disorders. Neuropsychopharmacology. 2021;46(13):2230\u20132.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"1670_CR286","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","volume":"76","author":"DE Falk","year":"2019","unstructured":"Falk DE, O\u2019Malley SS, Witkiewitz K, Anton RF, Litten RZ, Slater M, et al. Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. JAMA Psychiat. 2019;76(4):374\u201381.","journal-title":"JAMA Psychiat"},{"issue":"12","key":"1670_CR287","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/acer.13897","volume":"42","author":"K Witkiewitz","year":"2018","unstructured":"Witkiewitz K, Kranzler HR, Hallgren KA, O\u2019Malley SS, Falk DE, Litten RZ, et al. Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder. Alcohol Clin Exp Res. 2018;42(12):2453\u201365.","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"1670_CR288","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2215-0366(17)30130-X","volume":"4","author":"DS Hasin","year":"2017","unstructured":"Hasin DS, Wall M, Witkiewitz K, Kranzler HR, Falk D, Litten R, et al. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3-year follow-up study in the US general population. Lancet Psychiatry. 2017;4(6):469\u201376.","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"1670_CR289","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/acer.12546","volume":"38","author":"K Mann","year":"2014","unstructured":"Mann K, Vollst\u00e4dt-Klein S, Reinhard I, Lem\u00e9nager T, Fauth-B\u00fchler M, Hermann D, et al. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res. 2014;38(11):2754\u201362.","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"1670_CR290","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/acer.14183","volume":"43","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz K, Roos CR, Mann K, Kranzler HR. Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol Clin Exp Res. 2019;43(11):2395\u2013405.","journal-title":"Alcohol Clin Exp Res"},{"key":"1670_CR291","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/164_2017_79","volume":"248","author":"RZ Litten","year":"2018","unstructured":"Litten RZ, Falk DE, Ryan ML, Fertig J, Leggio L. Advances in pharmacotherapy development: human clinical studies. Handb Exp Pharmacol. 2018;248:579\u2013613.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"1670_CR292","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/acer.12669","volume":"39","author":"RZ Litten","year":"2015","unstructured":"Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res. 2015;39(4):579\u201384.","journal-title":"Alcohol Clin Exp Res"},{"issue":"24","key":"1670_CR293","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2174\/0929867323666161202092908","volume":"24","author":"R Agabio","year":"2017","unstructured":"Agabio R, Pisanu C, Gessa GL, Franconi F. Sex differences in alcohol use disorder. Curr Med Chem. 2017;24(24):2661\u201370.","journal-title":"Curr Med Chem"},{"key":"1670_CR294","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/bs.pbr.2015.07.023","volume":"224","author":"M Heilig","year":"2016","unstructured":"Heilig M, Leggio L. What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Prog Brain Res. 2016;224:401\u201318.","journal-title":"Prog Brain Res"},{"issue":"12","key":"1670_CR295","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S2215-0366(19)30222-6","volume":"6","author":"A Castillo-Carniglia","year":"2019","unstructured":"Castillo-Carniglia A, Keyes KM, Hasin DS, Cerd\u00e1 M. Psychiatric comorbidities in alcohol use disorder. Lancet Psychiatry. 2019;6(12):1068\u201380.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1670_CR296","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjmed.2016.10.004","volume":"130","author":"L Leggio","year":"2017","unstructured":"Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130(2):124\u201334.","journal-title":"Am J Med"},{"issue":"51","key":"1670_CR297","doi-asserted-by":"crossref","first-page":"25974","DOI":"10.1073\/pnas.1908137116","volume":"116","author":"A Guillot","year":"2019","unstructured":"Guillot A, Ren T, Jourdan T, Pawlosky RJ, Han E, Kim S-J, et al. Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking. Proc Natl Acad Sci USA. 2019;116(51):25974\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1670_CR298","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1530-0277.2008.00658.x","volume":"32","author":"L Tampier","year":"2008","unstructured":"Tampier L, Quintanilla ME, Israel Y. Tolerance to disulfiram induced by chronic alcohol intake in the rat. Alcohol Clin Exp Res. 2008;32(6):937\u201341.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1\u20133","key":"1670_CR299","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(96)00174-4","volume":"305","author":"R Spanagel","year":"1996","unstructured":"Spanagel R, H\u00f6lter SM, Allingham K, Landgraf R, Zieglg\u00e4nsberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 1996;305(1\u20133):39\u201344.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"1670_CR300","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0014-2999(96)00175-6","volume":"305","author":"R Spanagel","year":"1996","unstructured":"Spanagel R, Putzke J, Stefferl A, Sch\u00f6bitz B, Zieglg\u00e4nsberger W. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol. 1996;305(1\u20133):45\u201350.","journal-title":"Eur J Pharmacol"},{"issue":"6\u20137","key":"1670_CR301","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00008877-200111000-00015","volume":"12","author":"JA Chester","year":"2001","unstructured":"Chester JA, Grahame NJ, Li TK, Lumeng L, Froehlich JC. Effects of acamprosate on sensitization to the locomotor-stimulant effects of alcohol in mice selectively bred for high and low alcohol preference. Behav Pharmacol. 2001;12(6\u20137):535\u201343.","journal-title":"Behav Pharmacol"},{"issue":"4","key":"1670_CR302","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1254\/jphs.13056FP","volume":"122","author":"K Kurokawa","year":"2013","unstructured":"Kurokawa K, Mizuno K, Shibasaki M, Higashioka M, Oka M, Hirouchi M, et al. Acamprosate suppresses ethanol-induced place preference in mice with ethanol physical dependence. J Pharmacol Sci. 2013;122(4):289\u201398.","journal-title":"J Pharmacol Sci"},{"issue":"67","key":"1670_CR303","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbi.2017.08.021","volume":"1","author":"JHW Jacobsen","year":"2018","unstructured":"Jacobsen JHW, Buisman-Pijlman FTA, Mustafa S, Rice KC, Hutchinson MR. The efficacy of (+)-Naltrexone on alcohol preference and seeking behaviour is dependent on light-cycle. Brain Behav Immun. 2018;1(67):181\u201393.","journal-title":"Brain Behav Immun"},{"issue":"128","key":"1670_CR304","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neuropharm.2017.09.028","volume":"1","author":"JHW Jacobsen","year":"2018","unstructured":"Jacobsen JHW, Buisman-Pijlman FT, Mustafa S, Rice KC, Hutchinson MR. Antagonising TLR4-TRIF signalling before or after a low-dose alcohol binge during adolescence prevents alcohol drinking but not seeking behaviour in adulthood. Neuropharmacology. 2018;1(128):460\u201373.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1670_CR305","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1476-5381.2011.01572.x","volume":"165","author":"Y Wu","year":"2012","unstructured":"Wu Y, Lousberg EL, Moldenhauer LM, Hayball JD, Coller JK, Rice KC, et al. Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. Br J Pharmacol. 2012;165(5):1319\u201329.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"1670_CR306","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/acer.13416","volume":"41","author":"J Montesinos","year":"2017","unstructured":"Montesinos J, Gil A, Guerri C. nalmefene prevents alcohol-induced neuroinflammation and alcohol drinking preference in adolescent female mice: role of TLR4. Alcohol Clin Exp Res. 2017;41(7):1257\u201370.","journal-title":"Alcohol Clin Exp Res"},{"issue":"16","key":"1670_CR307","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1111\/bph.13526","volume":"173","author":"J Calleja-Conde","year":"2016","unstructured":"Calleja-Conde J, Echeverry-Alzate V, Gin\u00e9 E, B\u00fchler K-M, Nadal R, Maldonado R, et al. Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood. Br J Pharmacol. 2016;173(16):2490\u2013505.","journal-title":"Br J Pharmacol"},{"key":"1670_CR308","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3389\/fphar.2019.00471","volume":"10","author":"JC Foo","year":"2019","unstructured":"Foo JC, Vengeliene V, Noori HR, Yamaguchi I, Morita K, Nakamura T, et al. drinking levels and profiles of alcohol addicted rats predict response to nalmefene. Front Pharmacol. 2019;10:471.","journal-title":"Front Pharmacol"},{"key":"1670_CR309","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fpsyt.2018.00475","volume":"9","author":"G Colombo","year":"2018","unstructured":"Colombo G, Gessa GL. Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals. Front Psychiatry. 2018;9:475.","journal-title":"Front Psychiatry."},{"issue":"3","key":"1670_CR310","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-003-1397-y","volume":"167","author":"G Colombo","year":"2003","unstructured":"Colombo G, Vacca G, Serra S, Brunetti G, Carai MAM, Gessa GL. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology. 2003;167(3):221\u20134.","journal-title":"Psychopharmacology"},{"issue":"Pt A","key":"1670_CR311","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neuropharm.2017.10.012","volume":"136","author":"P Maccioni","year":"2018","unstructured":"Maccioni P, Lorrai I, Contini A, Leite-Morris K, Colombo G. Microinjection of baclofen and CGP7930 into the ventral tegmental area suppresses alcohol self-administration in alcohol-preferring rats. Neuropharmacology. 2018;136(Pt A):146\u201358.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1670_CR312","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF03033315","volume":"6","author":"G Colombo","year":"2004","unstructured":"Colombo G, Addolorato G, Agabio R, Carai MAM, Pibiri F, Serra S, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res. 2004;6(5):403\u201314.","journal-title":"Neurotox Res"},{"issue":"2","key":"1670_CR313","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.alcohol.2008.01.001","volume":"42","author":"P Maccioni","year":"2008","unstructured":"Maccioni P, Pes D, Fantini N, Carai MAM, Gessa GL, Colombo G. gamma-Hydroxybutyric acid (GHB) suppresses alcohol\u2019s motivational properties in alcohol-preferring rats. Alcohol. 2008;42(2):107\u201313.","journal-title":"Alcohol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01670-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:11:13Z","timestamp":1700197873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01670-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":313,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01670-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"21 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported in part by the National Institute on Alcohol Abuse and Alcoholism (K24AA025704 to LAR; F31AA028976 to EMB; F32AA029288 to SJN).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article was conceptualized by LAR, ENG, and EMB. Literature review and original draft preparation was conducted by EMB, ENG, SJN, and LRM. All authors reviewed and commented on previous versions of the manuscript, and all authors read and approved the final manuscript. All authors agree to be accountable for the work presented in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}